Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

ObjectiveTo explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment.MethodsMulticenter prospective study including 57 RRMS patients treated...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Paulette Esperanza Walo-Delgado, Enric Monreal, Silvia Medina, Ester Quintana, Susana Sainz de la Maza, José Ignacio Fernández-Velasco, Paloma Lapuente, Manuel Comabella, Lluis Ramió-Torrentà, Xavier Montalban, Luciana Midaglia, Noelia Villarrubia, Angela Carrasco-Sayalero, Eulalia Rodríguez-Martín, Ernesto Roldán, José Meca-Lallana, Roberto Alvarez-Lafuente, Jaime Masjuan, Lucienne Costa-Frossard, Luisa Maria Villar
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Frontiers Media S.A. 2021-10-01
Saila:Frontiers in Immunology
Gaiak:
multiple sclerosis
side effects
autoimmunity
disease modifying treatments
alemtuzumab
biomarkers
Sarrera elektronikoa:https://www.frontiersin.org/articles/10.3389/fimmu.2021.760546/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.760546/full

Antzeko izenburuak